Medherant Announces Appointment of New Chair
Coventry, UK, 6th February 2017 / Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, is pleased to announce the appointment of Dr Ken Cunningham as Chair. Dr Cunningham joins Medherant...
Medherant Ltd. Completes £1.5M Fundraising Round for Transdermal Drug Delivery Platform
Coventry, UK, 27th September 2016 / Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, has completed a funding round worth £1.5M, including a direct investment of £650,000 from ...
Medherant Shortlisted for ON Helix BioNewsRound 2016 Award
Medherant were recently shortlisted for the ON Helix BioNewsRound 2016 Award; an award which recognises the biotech related press releases which have had the most impact over the previous year. Medherant were selected for their press release in...
Mercia Makes Follow-on Investment in Medherant’s Novel Transdermal Technology
Henley-in-Arden, UK, 5th May 2016 / Mercia Fund Management (‘Mercia’), a leading investment business in UK innovation and wholly-owned subsidiary of Mercia Technologies PLC, has committed follow-on capital to Medherant Ltd, a University of W...
Medherant On Thomson Reuters TV
Ibuprofen Patch Heralds Side Effect Free Drug Future https://www.reuters.com/assets/iframe/yovideo?videoId=367483153 This video was published on Thomson Reuters TV on February 22, 2016. Copyright @Thomson Reuters, 2016....
Medherant’s First Ibuprofen Patch – TEPI Patch Technology
Researchers at the University of Warwick have worked with Coventry-based Medherant, a Warwick spinout company, to produce and patent the World’s first ever ibuprofen patch delivering the drug directly through skin to exactly where it is needed...
Interview with Mercia and Medherant by MedNous
Capital Start for University of Warwick Spin-Out Download article As universities have become better at organising their theoretical research into commercial propositions, intermediaries have appeared on the scene to nurture their research unti...
Medherant @BioEurope 2015
Medherant had a very successful trip to BioEurope in Munich on the 2-4 November. Whilst there we gave a short pitch in the Emerging Technologies Forum to introduce the Medherant technology platform and to showcase our early results in the devel...
Medherant Signs License Agreement With Bostik And Secures Seed Investment From Mercia For Development Of Next Generation Transdermal Drug Delivery Systems
New bio-adhesive company Medherant, founded by Warwick Ventures for the University of Warwick, UK, in 2014, has signed a license agreement with the leading global adhesive specialists Bostik. The partnership will supplement Medherant's capabilities t...